(1 mg/ml) at a dose of 0-3 mg/kg three times a day before meals with placebo syrup, which was identical to Cisapride in taste and appearance, taken at the same dose, over eight weeks. In each patient diagnosis of gastro-oesophageal reflux was based on pH-metric demonstration of acid reflux. Fibreoptic endoscopy and biopsy examination revealed oesophagitis in all 20 patients. Infectious, neurologic, metabolic, and renal disorders were carefully excluded. Abnormalities of the oesophagus, stomach, and duodenum were excluded by upper intestinal x ray examination. Parents gave informed consent and the study was approved by the ethical committee of our faculty.
SUMMARY Twenty children (age range 75 days-47 months) with reflux oesophagitis entered a random double blind trial in which they received either Cisapride (Janssen Pharmaceutical Ltd), a new prokinetic agent, or an identical placebo syrup. Diagnosis of gastro-oesophageal reflux was made by measurement of intraluminal oesophageal pH combined with manometry. Oesophagitis was assessed in all patients by histological examination of mucosal specimens taken during oesophagogastroduodenoscopy. Manometry, pH test, and endoscopy with biopsy examination were repeated at the end of the treatment period. Seventeen patients completed the trial, eight of whom were taking the drug and nine the placebo. Mean total clinical score and post-prandial reflux time (% of reflux) significantly improved in patients in the group given Cisapride but not in the group given placebo. Furthermore, there was a significant improvement of the histological oesophagitis score only in the children in the group given Cisapride, whereas placebo was ineffective. It is concluded that Cisapride is a useful agent both for the relief of symptoms of gastro-oesophageal reflux and for the healing of peptic oesophagitis in infancy.
In the past few years there have been a number of studies on gastro-oesophageal reflux in children. '-3 Interest has been concentrated mainly on the clinical presentation and on providing reliable diagnostic tests. A few studies, however, have been directed towards assessing the therapeutic approach of the disease. Recent (1 mg/ml) at a dose of 0-3 mg/kg three times a day before meals with placebo syrup, which was identical to Cisapride in taste and appearance, taken at the same dose, over eight weeks. In each patient diagnosis of gastro-oesophageal reflux was based on pH-metric demonstration of acid reflux. Fibreoptic endoscopy and biopsy examination revealed oesophagitis in all 20 patients. Infectious, neurologic, metabolic, and renal disorders were carefully excluded. Abnormalities of the oesophagus, stomach, and duodenum were excluded by upper intestinal x ray examination. Parents gave informed consent and the study was approved by the ethical committee of our faculty.
Gastro-oesophageal reflux was detected by a five hour pH study, performed after ingestion of apple juice (15-20 cc/kg), with a pH of 4. A small flexible electrode (MI 506, Microelectrodes Inc, Londonderry, New Hampshire, United States of America), calibrated with buffers at pH levels of 7 0 and 4-0, was introduced nasally and located at 87% of the distance from the nares to the lower oesophageal sphincter previously determined by manometry. Gastro-oesophageal reflux was defined as a fall in intra-oesophageal pH below 4 for at least 20 seconds.
Manometry was performed by a triple lumen catheter with side recording orifices spaced 2-5 cm apart and perfused with bubble free water at a low compliance infusion system (Arndorfer, Med Spec Co, Greendale, Wisconsin, USA). The probe was initially located into the stomach and subsequently moved across the lower oesophageal sphincter 0*5 cm at a time, remaining at each station long enough to obtain a stable pressure recording. Lower oesophageal sphincter pressure was determined as mean pressure of the three orifices, with the gastric pressure as zero reference, taking the mid-respiratory value. Motor activity of the distal oesophagus was recorded by placing the distal side hole of the catheter immediately proximal to the lower oesophageal sphincter. Oesophageal waves were elicited by administering 2 ml of 5% dextrose. Only waves preceded by at least 30 seconds of silent motor activity in the oesophagus were taken into account. Amplitude of peristalsis (mm Hg) was measured by subtracting the mean resting oesophageal pressure from the peak of the waves. Both oesophageal manometry and pH study were performed during the same session after a two to three hour fast without sedation. Patients with diagnosis of reflux underwent upper endoscopy with a small fibreoptic endoscope (GIF PX Olympus).
Mucosal erythema or oedema were not considered to be reliable findings of oesophagitis. Endoscopic lesions, such as friability, exudate, erosions, or ulcerations, were considered to be important markers of oesophagitis. During endoscopy, biopsy specimens were taken from the oesophageal mucosa, irrespective of its appearance, and examined by a histopathologist, who was unaware of the endoscopic findings. The degree of oesophagitis was histologically defined as 'mild' if there was basal cell hyperplasia and extension of the papillae, 'moderate' if there was also an increased cellularity of the lamina propia, and 'severe' if there were also signs of mucosal ulcerations.
Blood counts, urinalysis, and determination of serum transaminase and alkaline phosphatase activities, and bilirubin, creatinine, and urea concentrations were taken before randomisation to either Cisapride or placebo. During the study, frequent assessments were made of severity and frequency of symptoms and drug use. Manometry, pH study, endoscopy, and biopsy examination were repeated within two days before the end of the trial for comparison with pretreatment data. At completion of the trial the patients were classified as 'cured' if clinical, pH-metric, and histological variables had normalised, 'improved' if at least one of these three variables had ameliorated, and 'unchanged' or 'worsened' if no improvement or worsening was observed, respectively. Throughout the trial, parents were provided with diary cards to keep a daily record of the symptoms and physical signs. A scoring system was used to evaluate symptoms and physical signs as well as oesophageal histology of the patients (Table 1) .
Data were analysed using either Student's t test or rank sum non-parametric tests. p Values <005
were considered significant.
Results
Three patients failed to complete the study and were withdrawn, two because of febrile upper respiratory infections and one who failed to take the drug continuously. Eight patients (age range 90 days-36 months) were treated with the drug and nine (age Cisapride caused a significant reduction of the reflux time, whereas mean duration of reflux was unchanged. This finding was mainly due to a decreased frequency of episodes of reflux and implies that the drug might be more effective on the mechanisms related to the frequency of episodes of reflux, such as lower oesophageal sphincter pressure and gastric emptying. Cisapride has also been shown to improve gastric emptying: documentation of this effect is lacking in our study.
Cisapride was also more effective than placebo in improving histological changes of oesophagitis. Of the 17 patients included in the study, however, only three had severe oesophagitis; the remaining 14 had mild or moderate oesophagitis. The effectiveness of Cisapride in the treatment of more severe reflux oesophagitis remains to be proved.
The manometric findings, such as normal (or slightly decreased) pressure of peristalsis and lower oesophageal sphincter absence of non-specific oesophageal motor defects, and the prevailing moderate degree of oesophagitis, indicate that our group of selected patients was not seriously affected. It would be desirable, therefore, for future trials with Cisapride in children affected by gastro-oesophageal reflux to include more patients with severe reflux oesophagitis.
